For Immediate Release
For more information contact:
Feinstein Kean Healthcare
Return Path Announces Philanthropic Partnership With The Accelerated Cure Project For Multiple Sclerosis
Leading Email Performance Company Partners With National Nonprofit Dedicated To Curing Multiple Sclerosis
New York, NY and Boston, MA- November 29, 2005 - Return Path, Inc., the leading email performance company, today announced a wide-ranging philanthropic partnership with the Accelerated Cure Project for Multiple Sclerosis, a national nonprofit dedicated to curing multiple sclerosis by determining its causes.
Inspired by a former employee diagnosed with MS, Return Path decided to focus the company's charitable donations and activities on an organization devoted to curing the disease. Accelerated Cure Project, founded in 2001, began as the Boston Cure Project for Multiple Sclerosis and branched out nationally in 2005 under the umbrella name Accelerated Cure Project for MS. Multiple Sclerosis is a demyelinating disorder of the central nervous system affecting over 400,000 people in the US and 2 million individuals worldwide. It often results in severe disability including the inability to walk, impaired vision or in some cases blindness, cognitive dysfunction, bladder and bowel problems, extreme fatigue and other serious symptoms.
The Accelerated Cure Project is focused on identifying the causes of MS. For its partnership with the Accelerated Cure Project, Return Path will aid the organization in a variety of ways, including: free use of relevant Return Path services to assist Accelerated Cure Project in its email communications with volunteers and donors; the ability for consumers who receive cash incentive payments for participating in surveys via Return Path's Survey Direct market research panel to donate those incentives to the Accelerated Cure Project; direct cash donations, including 50 percent of all royalties Return Path receives from Sign Me Up!, a book on email marketing that the company published earlier this year; and paid-time-off volunteer support from Return Path employees for Accelerated Cure Project events in New York or Denver.
"Seeing a good friend and long-time employee who was affected by MS was a very moving experience for us," said Matt Blumberg, Chairman and CEO of Return Path. "We decided to rally our employees and resources to support those researching a cure for MS, and the minute we met the team at Accelerated Cure, we knew we had found a great partner."
"Return Path's enthusiastic support of our mission to identify the causes of MS has been a tremendous boost to our efforts," said Art Mellor, President and CEO of Accelerated Cure Project. "Their services have connected us with hundreds of new supporters and helped individuals affected by MS find valuable resources provided on our web site."
About Return Path
Return Path is an e-mail performance management company dedicated to improving the reach, delivery performance and overall success of permission-based e-mail programs. More than 1,500 companies use Return Path's services to generate superior results from their e-mail programs, taking advantage of Return Path's pioneering innovation in deliverability, ECOA, list hygiene, double-opt-in list acquisition and best practices strategy. Solutions include list maintenance, deliverability, data acquisition, online sampling, marketing technology and e-mail strategy. Return Path's Postmaster Direct file is the largest, most targeted double opt-in database available for e-mail acquisition. The company's investors include Sutter Hill Ventures, Mobius Venture Capital, Flatiron Partners, and JP Morgan Partners. For more information, please visit www.returnpath.net
, e-mail firstname.lastname@example.org
, or call toll-free 866-362-4577.
About Accelerated Cure Project
Accelerated Cure Project for MS (ACP) is a nonprofit organization whose mission is to accelerate efforts toward a cure for multiple sclerosis (MS) by rapidly advancing research that determines its causes and mechanisms. We provide biomedical researchers with resources that catalyze open scientific collaboration and enable them to explore their novel research ideas rapidly and cost-efficiently. ACP’s strategic initiatives include the Multiple Sclerosis Discovery Forum and the ACP Repository, a large-scale collection of highly-characterized biosamples available to scientists at any organization conducting research that contributes to our mission. All results generated through analysis of Repository samples and data are contributed back to the ACP Repository Database, resulting in an increasingly valuable and comprehensive information resource that can be analyzed to reveal new insights about MS. To date, ACP has enrolled almost 3,000 participants into the Repository through a network of 10 MS clinical centers across the United States. The samples provided by people with MS and related disorders have supported more than 60 research studies worldwide and generated more than 150 million returned data points.
About Multiple Sclerosis
Multiple Sclerosis is a chronic demyelinating disorder of the central nervous system that often results in severe disability including the inability to walk, blindness, cognitive dysfunction, extreme fatigue, and other serious symptoms. MS affects more than 400,000 people in the US and two million individuals worldwide. The disorder occurs twice as often in women as in men. What causes MS is undetermined and no cure has yet been developed.